AbbVie Financial Statements
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
After hours: 276.43 -0.01%
AbbVie revenue and earnings
In fiscal 2025, AbbVie generated $61.16 billion in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $4.23 billion (-1.2% year over year), for a net margin of 6.9% versus a median of 10.1% in the prior 5 years. Gross margin was 70.2% (up from 70.0%) and operating margin 24.6%.
Diluted earnings per share came in at $2.36, down from $2.39. Over the last 5 fiscal years, ABBV's revenue has grown at a 6.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
AbbVie income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.16B | 56.33B | 54.32B | 58.05B | 56.20B | 45.80B | 33.27B | 32.75B | 28.22B | 25.64B |
| Revenue growth (YoY) | +8.57% | +3.71% | -6.44% | +3.30% | +22.69% | +37.69% | +1.57% | +16.08% | +10.06% | +12.16% |
| Cost of Revenue | 18.20B | 16.90B | 20.41B | 17.41B | 17.45B | 15.39B | 7.44B | 7.72B | 7.04B | 5.83B |
| Gross Profit | 42.96B | 39.43B | 33.90B | 40.64B | 38.75B | 30.42B | 25.83B | 25.04B | 21.17B | 19.81B |
| Operating Expenses | 27.88B | 30.29B | 21.15B | 22.52B | 20.83B | 19.05B | 12.84B | 18.65B | 11.63B | 10.47B |
| Research & Development | 9.10B | 12.79B | 7.67B | 6.51B | 6.92B | 6.38B | 6.41B | 10.33B | 5.01B | 4.38B |
| Selling, General & Admin | 14.01B | 14.75B | 12.87B | 15.26B | 12.35B | 11.30B | 6.94B | 7.40B | 6.29B | 5.88B |
| Operating Income | 15.07B | 9.14B | 12.76B | 18.12B | 17.92B | 11.36B | 12.98B | 6.38B | 9.54B | 9.34B |
| Interest Expense | 2.89B | 2.81B | 2.22B | 2.23B | 2.42B | 2.45B | 1.78B | 1.35B | 1.15B | 1.05B |
| Other Income (Expense) | -5.79B | -3.24B | -4.68B | -2.45B | -2.50B | -5.61B | -3.01B | -18.00M | -466.00M | -188.00M |
| Pretax Income | 6.60B | 3.72B | 6.25B | 13.48B | 12.99B | 3.40B | 8.43B | 5.20B | 7.73B | 7.88B |
| Income Tax | 2.36B | -570.00M | 1.38B | 1.63B | 1.44B | -1.22B | 544.00M | -490.00M | 2.42B | 1.93B |
| Net Income | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B | 4.62B | 7.88B | 5.69B | 5.31B | 5.95B |
| Net Income growth (YoY) | -1.22% | -12.03% | -58.91% | +2.55% | +150.04% | -41.44% | +38.60% | +7.12% | -10.82% | +15.73% |
| EPS (Basic) | 2.37 | 2.40 | 2.73 | 6.65 | 6.48 | 2.73 | 5.30 | 3.67 | 3.31 | 3.65 |
| EPS (Diluted) | 2.36 | 2.39 | 2.72 | 6.63 | 6.45 | 2.72 | 5.28 | 3.66 | 3.30 | 3.63 |
| Shares Outstanding (Basic) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.67B | 1.48B | 1.54B | 1.60B | 1.62B |
| Shares Outstanding (Diluted) | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B | 1.55B | 1.60B | 1.63B |
| EBITDA | 15.84B | 9.90B | 13.51B | 18.89B | 18.73B | 12.03B | 13.45B | 6.85B | 9.97B | 9.77B |
| Gross Margin | 70.24% | 69.99% | 62.42% | 70.00% | 68.96% | 66.41% | 77.64% | 76.44% | 75.04% | 77.25% |
| Operating Margin | 24.65% | 16.22% | 23.49% | 31.21% | 31.89% | 24.81% | 39.03% | 19.49% | 33.83% | 36.43% |
| Net Margin | 6.91% | 7.59% | 8.95% | 20.39% | 20.54% | 10.08% | 23.69% | 17.36% | 18.82% | 23.22% |
This table shows 10 annual periods of AbbVie's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ABBV's reporting calendar. What is a income statement?